



NDA 203388/S-016

SUPPLEMENT APPROVAL

Genentech, Incorporated
Attention: Loan Ly
Regulatory Program Management
1 DNA Way
South San Francisco, CA 94080

Dear Ms. Ly:

Please refer to your supplemental new drug application (sNDA) dated and received February 14, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Erivedge (vismodegib) capsule.

This Prior Approval supplemental new drug application provides for revisions to Section 2 Dosage and Administration: Subsection 2.3 Dosage Modifications for Adverse Reactions, Section 5 Warnings and Precautions: Subsection 5.2 Severe Cutaneous Adverse Reactions, Section 6 Adverse Reactions: Subsection 6.2 Post Marketing Experience, and Section 17 Patient Counseling Information of the Full Prescribing Information (FPI) with corresponding changes to the Medication Guide, to add a new adverse reaction of Severe Cutaneous Adverse Reactions. In addition, Highlights of Prescribing Information was updated to reflect revisions made to the FPI and minor formatting edits were made throughout the FPI.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [FDA.gov](http://www.fda.gov).¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Rebecca Cohen, Regulatory Health Project Manager, at (240) 402-4998.

Sincerely,

{See appended electronic signature page}

Abhilasha Nair, M.D.
Associate Director for Safety (Acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ABHILASHA NAIR
07/31/2020 10:54:40 AM